4 results
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
* Primary Objective:To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment* Secundary Objective: - To assess the effect of MEDI0382 on hepatic glycogen levels versus…